Herbalife

Global Regulatory Scrutiny Will Undermine MLM And Supplement Models

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

24 Sep 24

Updated

27 Nov 25

n/a

AnalystConsensusTarget's Fair Value

n/a

53.3%

-4.2%

53.3%

-4.2%

You can edit this narrative until Nov 28 11:10 AM. Then, changes will post as Updates.

Author's Valuation

US$9.6726.2% overvalued

AnalystConsensusTarget Fair Value

Narrative

Updates3

Shared on 27 Nov 25

Fair value Increased 3.57%

HLF: Uncertainty Around CEO Transition Will Challenge Near-Term Momentum

Herbalife’s analyst price target has been raised to $11 from $10, as analysts point to recovering fundamentals and the company’s strategic leadership changes as promising signs for future growth. Analyst Commentary Analysts have recently weighed in on Herbalife, offering a mix of optimism about its improving fundamentals and some caution about ongoing risks.

Shared on 19 Mar 25

Fair value Increased 6.18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Increased 1.42%

AnalystConsensusTarget has increased revenue growth from 1.7% to 3.1%, decreased profit margin from 5.9% to 3.9% and increased future PE multiple from 4.2x to 5.9x.

AnalystConsensusTarget Fair Value

US$9.67

26.2% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.51%

Personal Products revenue growth rate

0.15%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.16%

Calculation

US$237.79m

Earnings '28

6.10x

PE Ratio '28

US$1.45b

Market Cap '28

US$1.45b

Market Cap '28

109.92m

No. shares '28

US$13.20

Share Price '28

US$13.20 Share Price '28

Discounted to 2025 @ 11.26% p.a.

US$9.59

Fair Value '25